To help address the need for more content-focused solutions to reach HCPs more effectively, Havas Health & You has formed a global partnership with Evermed, a technology company whose modular content hubs power personalized video content delivery for life science companies and HCPs.
If you are not happy with the results below please do another search
50 search results for:
The company is developing brain chip interfaces that it says could help disabled patients to move and communicate again, with Musk adding it will also target restoring vision.
PictorLabs emerged from stealth mode Thursday with $15 million to advance its AI-powered virtual staining platform that researchers hope will “reimagine the future” of histopathology.
The investment to expand manufacturing at Pfizer’s plant in Dublin would double its capacity to produce key substances used in biological drugs.
The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to “persist” until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil.
Under the terms, biotech firm Roivant will be responsible for funding the development and will retain commercialization rights for RVT-3101, once approved, in the United States and Japan.
World AIDS Day on December 1 is an opportunity for people worldwide to unite in the fight against HIV and AIDS. It’s also time to take stock, be honest, and realize that we still have work to do to protect our communities.
The Ireland-based company issued a statement confirming that it is engaged in “highly preliminary discussions” with Amgen, Janssen, and Sanofi. Any acquisition of Horizon Therapeutics would be among the biggest deals of 2022.
The therapy, Rebyota, targets Clostridium difficile, or C. difficile – a superbug responsible for infections that can cause serious and life-threatening diarrhea. In the United States, the infection is associated with 15,000-30,000 deaths annually.
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.